TABLE 2.
Patient characteristics of the HER2‐positive cohort
| Characteristics | HER2 amplification cohort | HER2 mutant cohort | |||||
|---|---|---|---|---|---|---|---|
| No. of cases (%) | No. of cases (%) | ||||||
| Trastuzumab in the Geneplus cohort (n = 40) | Pyrotinib studies in HER2‐amplification patients (n = 46) a | Anti‐HER2 antibody drugs in the MSKCC‐BREAST cohort (n = 188) | Lapatinib in the MSKCC‐BREAST cohort (n = 45) | Pyrotinib investigator‐initiated clinical study (n = 11) | MutHER study (n = 14) b | Summit study (n = 25) | |
| Age at initial diagnosis | |||||||
| ≤35 years | 12 (30.0) | 10 (21.7) | 28 (14.9) | 5 (11.1) | 0 (0.0) | NA | NA |
| >35 years | 28 (70.0) | 36 (78.3) | 160 (85.1) | 40 (88.9) | 11 (100.0) | NA | NA |
| Histopathology | |||||||
| Invasive ductal carcinoma | 33 (82.5) | 42 (91.3) | 151 (80.3) | 33 (73.3) | 11 (100.0) | NA | 17 (68.0) |
| Invasive lobular carcinoma | 1 (2.5) | 0 (0.0) | 17 (9.0) | 4 (8.9) | 0 (0.0) | NA | 6 (24.0) |
| Other | 6 (15.0) | 4 (8.7) | 20 (10.6) | 8 (17.8) | 0 (0.0) | 0 (0.0) | 2 (8.0) |
| HR status | |||||||
| Positive | 22 (55.0) | 19 (41.3) | 118 | 25 (55.6) | 11 (100.0) | ‐ | ‐ |
| Negative | 18 (45.0) | 27 (58.7) | 64 | 17 (37.8) | 0 (0.0) | ‐ | ‐ |
| NA | 0(0.0) | 0 (0.0) | 6 (3.2) | 3 (6.7) | 0 (0.0) | 14 (100.0) | 25 (100.0) |
| Visceral metastasis | |||||||
| Yes | 25 (62.5) | 34 (73.9) | NA | NA | 7 (63.6) | NA | NA |
| No | 15 (37.5) | 12 (26.1) | NA | NA | 4 (36.4) | NA | NA |
| Pre anti‐HER2 treatment | |||||||
| Yes | 28 (70.0) | 27 (58.7) | NA | NA | 4 (36.4) | NA | NA |
| No | 12 (30.0) | 19 (41.3) | NA | NA | 7 (63.6) | NA | NA |
| TP53 status | |||||||
| Positive | 20 (50.0) | 27 (58.7) | 104 (55.3) | 28 (62.2) | 6 (54.5) | 5 (35.7) | 7 (28.0) |
| Negative | 20 (50.0) | 19 (41.3) | 84 (44.7) | 19 (37.8) | 5 (45.5) | 9 (64.3) | 18 (72.0) |
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MSKCC, Memorial Sloan Kettering Cancer Center.
a
Including phase Ib, Ic, and II.
b
Since the clinical information given in the original text (16 patients) included 2 HER2 mutations of unknown significance, the author did not provide the mutation and clinical information of these two patients, so the clinical information of the 14 patients included in the mutation analysis could not be determined.